

## GP10106, Mu Opioid Receptor, IHC Protocol:

- 1. Rats were deeply anesthetized with isoflurane and perfused through the aortic arch with 100 ml of heparin (75 U/ml of heparin in 0.9% saline) followed by 100 ml of a mixture of 3.75% acrolein and 2% PFA in 0.1 M PB, pH 7.4, and then by 300 ml of 2% PFA in the same buffer at 45 ml/min.m Lumbar spinal cord was removed and postfixed in 2% PFA in 0.1 M PB for 1 h at 4°C. Sections (50 μm thick) were cut using a Vibratome and processed for MOR labeling.
- 2. Sections were incubated in 1% sodium borohydride for 30 min and extensively rinsed in 0.1 M PB. They were then cryoprotected for 30 min in a solution consisting of 25% sucrose and 3% glycerol in 0.05 M PB and snap frozen with isopentane (–50°C) followed by liquid nitrogen.
- 3. After being rapidly thawed in 0.1 M PB, sections were rinsed with TBS 0.1M and preincubated for 1 h at room temperature in 3% NGS diluted in TBS. They were then incubated for 36 h at 4°C in MOR antiserum diluted 1/500 in TBS containing 0.5% NGS. Sections were then rinsed twice with TBS and incubated for 1 h at room temperature with biotinylated anti-guinea pig antibody (1/400; Vector Laboratories).
- 4. Following three 10 min washes in TBS, sections were incubated 30 min with Vectastain Elite ABC (Vector Laboratories). Sections were rinsed three times with TBS and peroxidase complex revealed for 8 minutes with DAB substrate (2.2 mg/10 ml + 0.01% H2O2).
- 5. At the end of this incubation, sections were washed twice with TBS, mounted on microscope slides, and dehydrated with ethanol.

Image and protocol Courtesy of Dr. Louis Gendron, University of Sherbrooke.



## FOR RESEARCH USE ONLY

NEUROMICS REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND

ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V4-02/2012

www.neuromics.com